Bioretec

We expect the company to show clear signs of growth this year.

The cost structure is being adjusted to reflect actual demand.

The company is seeking additional savings of 0.2 MEUR, as production capacity is still too high relative to demand.

7:09

Bioretec's Q1 earnings positively surprised in terms of revenue and profit, particularly due to growth in the US and European markets.

Bioretec's start to the year offered a positive surprise.

In the report, our attention is drawn to the development of RemeOs sales in Europe and the United States.

The share issue secures funding at least until mid-2027.